- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04678336
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Pediatric Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1 study to determine the safety, manufacturing feasibility, and efficacy of CART123 cells following lymphodepleting chemotherapy in pediatric subjects with relapsed/refractory AML.
Subjects will receive CART123 cells via a single IV infusion at a dose of 2x10^6 CART123 cells/kg, following lymphodepleting chemotherapy. The total dose administered to each subject will be based on the subject's body weight obtained at the time of apheresis. The minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg.
There will be a 28-day stagger between the first 3 subject infusions, such that the next subject may not receive treatment (lymphodepleting chemotherapy plus CART123 cells) until the previous subject has completed their Day 28 safety follow-up visit and a DLT assessment has been performed. Subsequent infusions will be staggered by a minimum of 14 days.
It is recommended that subjects with marrow aplasia at Day 28+/-5 undergo an allogeneic hematopoietic cell transplantation (alloHCT) as a rescue strategy. If required, this procedure will be performed as part of routine care, outside of the scope of this research study; however, subjects will continue to be followed onstudy. All subjects must, therefore, have a previously identified stem cell donor as part of their eligibility to participate in this study.
All subjects will be followed monthly for up to 6 months after the CART123 cell infusion (Day 0). Thereafter, subjects will be transitioned into LTFU for up to 15 years post infusion.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients ≥ 1 and ≤ 29 years of age at time of consent.
AML in second or greater relapse, post-transplant relapse, or chemotherapy-refractory disease. Specifically:
- Second or greater relapse defined as flow cytometric confirmation of myeloid leukemia of at least 0.1% after second documented complete remission; OR
- Any detectable disease post-allogeneic transplant with flow cytometric confirmation (MRD) of myeloid leukemia of at least 0.1%; OR
- Refractory disease, defined as persistent bone marrow involvement with >5% blasts after two courses of induction chemotherapy for patients at initial presentation or >5% bone marrow blasts after one course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR.
- Subjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor.
Adequate organ function defined as:
a. A serum creatinine based on age/gender b. Adequate liver function i. ALT ≤ 5 x ULN ii. Total bilirubin ≤ 3 x ULN iii. ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver.
c. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and < Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator d. Left Ventricular Shortening Fraction (LVSF) ≥ 28% or Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO, or adequate ventricular function documented by a scan or a cardiologist. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice.
- Adequate performance status defined as Lansky or Karnofsky score ≥ 50
- Signed informed consent must be obtained.
- No contraindications for leukapheresis (unless apheresis product previously acquired).
- Subjects of reproductive potential must agree to use acceptable birth control methods.
Exclusion Criteria:
- Pregnant or lactating (nursing) women.
- Patients with relapsed AML with t(15:17).
- Patients must be > 6 months from alloHSCT.
- HIV infection.
- Active hepatitis B or hepatitis C infection.
- Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy
- Concurrent use of systemic steroids at the time of cell infusion or cell collection or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
- Any uncontrolled active medical disorder that would preclude participation as outlined.
- Uncontrolled active infection
- Subjects with CNS3 disease that is progressive on therapy or with CNS parenchymal lesions that may increase the risk of CNS toxicity. Subjects with adequately treated CNS leukemia are eligible.
- Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).
- Patients with any prior history of myeloproliferative neoplasm.
- Patients with somatic JAK2 V617F mutation by PCR or next generation sequencing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
CART123 cells; cyclophosphamide; fludarabine
|
CART123 cells following lymphodepleting chemotherapy in pediatric patients with relapsed/refractory AML.
Subjects will be treated with a single IV dose of CART123 cells on Day 0.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of CART123 in AML subjects
Time Frame: 5 Years
|
Occurrence of adverse events that are possibly, probably, or definitely related to CART123 cells
|
5 Years
|
Manufacturing feasibility
Time Frame: 5 Years
|
Percentage of manufacturing products that meet release criteria
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of CART123 cells in AML subjects evaluated by ORR at Day 28 using standard clinical criteria
Time Frame: 15 Years
|
Overall Response Rate (ORR) at 28 +/- 5 days
|
15 Years
|
Efficacy of CART123 cells in AML subjects evaluated by reduction of blast count in the peripheral blood and marrow using standard clinical criteria and flow cytometry
Time Frame: 15 Years
|
Change of blast count in the peripheral blood and marrow using standard clinical criteria (CBC with differential count, marrow aspirate with differential count) and flow cytometry
|
15 Years
|
Overall survival (OS)
Time Frame: 15 Years
|
Overall survival (OS) for all subjects
|
15 Years
|
Progression-Free Survival (PFS)
Time Frame: 15 Years
|
Progression-free survival (PFS) for all subjects; PFS will be followed until the time of first relapse or receipt of additional therapy, excluding alloHCT for marrow aplasia.
|
15 Years
|
Duration of response (DOR)
Time Frame: 15 Years
|
Time between date of when the response criteria of CR/CRi was met to the date of relapse
|
15 Years
|
Need for rescue alloHCT
Time Frame: 15 Years
|
Percentage of subjects proceeding to alloHCT (or second allogeneic HCT)
|
15 Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine persistence and trafficking of CART123 cells
Time Frame: 15 Years
|
The duration of in vivo survival of CART123 cells ("persistence") is defined as the period of time above the limit of detection of Q-PCR for peripheral blood CART123 transgene sequences and/or flow cytometry for scFv surface expression.
|
15 Years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- 834675 (19CT011)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia, in Relapse
-
University of FreiburgCompletedAcute Myeloid Leukemia, in RelapseGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid LeukemiaUnited States
-
UNC Lineberger Comprehensive Cancer CenterMerck Sharp & Dohme LLCActive, not recruitingAcute Myeloid Leukemia, in RelapseUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
St. Jude Children's Research HospitalAbbVie; Gateway for Cancer Research; Karyopharm Therapeutics IncRecruitingRefractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous LineageUnited States
-
All India Institute of Medical Sciences, New DelhiUnknown
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
Clinical Trials on CART123 cells; cyclophosphamide; fludarabine
-
University of PennsylvaniaRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, RefractoryUnited States
-
Affiliated Hospital to Academy of Military Medical...UnknownAdult Acute Myeloid LeukemiaChina
-
Baylor College of MedicineNational Cancer Institute (NCI); The Methodist Hospital Research Institute; Center...Active, not recruitingEBV-positive Nasopharyngeal CarcinomaUnited States
-
Tongji HospitalNanjing IASO Biotechnology Co., Ltd.RecruitingMultiple Sclerosis | Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Autoimmune Encephalitis | Idiopathic Inflammatory Myopathies | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Myelin Oligodendrocyte Glycoprotein... and other conditionsChina
-
Huazhong University of Science and TechnologyShanghai IASO Biotechnology Co., LtdNot yet recruitingChronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
-
Chinese PLA General HospitalRecruiting
-
Wuhan Union Hospital, ChinaBeijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.RecruitingT-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin LymphomaChina
-
Wuhan Union Hospital, ChinaShanghai Simnova Biotechnology Co.,Ltd.RecruitingChronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's LymphomaChina
-
Wuhan Union Hospital, ChinaChengdu USino Technology Biology Co., LtdRecruitingB-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic LeukemiaChina
-
Wuhan Union Hospital, ChinaGuangzhou Bio-gene Technology Co., LtdRecruiting